Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.

TitleHodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.
Publication TypeJournal Article
Year of Publication2007
AuthorsChiu A, Xu W, He B, Dillon SR, Gross JA, Sievers E, Qiao X, Santini P, Hyjek E, Lee J-won, Cesarman E, Chadburn A, Knowles DM, Cerutti A
JournalBlood
Volume109
Issue2
Pagination729-39
Date Published2007 Jan 15
ISSN0006-4971
KeywordsB-Cell Activating Factor, B-Cell Maturation Antigen, B-Lymphocytes, Cell Line, Tumor, Cell Proliferation, Cell Survival, Gene Expression Profiling, Hodgkin Disease, Humans, Immunophenotyping, Reverse Transcriptase Polymerase Chain Reaction, RNA Interference, Signal Transduction, Transmembrane Activator and CAML Interactor Protein, Tumor Necrosis Factor Ligand Superfamily Member 13
Abstract

Hodgkin lymphoma (HL) originates from the clonal expansion of malignant Hodgkin and Reed-Sternberg (HRS) cells. These B-cell-derived elements constitute less than 10% of the tumoral mass. The remaining tissue is comprised of an inflammatory infiltrate that includes myeloid cells. Myeloid cells activate B cells by producing BAFF and APRIL, which engage TACI, BCMA, and BAFF-R receptors on the B cells. Here, we studied the role of BAFF and APRIL in HL. Inflammatory and HRS cells from HL tumors expressed BAFF and APRIL. Unlike their putative germinal center B-cell precursors, HRS cells lacked BAFF-R, but expressed TACI and BCMA, a phenotype similar to that of plasmacytoid B cells. BAFF and APRIL enhanced HRS cell survival and proliferation by delivering nonredundant signals via TACI and BCMA receptors through both autocrine and paracrine pathways. These signals caused NF-kappaB activation; Bcl-2, Bcl-xL, and c-Myc up-regulation; and Bax down-regulation, and were amplified by APRIL-binding proteoglycans on HRS cells. Interruption of BAFF and APRIL signaling by TACI-Ig decoy receptor, which binds to and neutralizes BAFF and APRIL, or by small-interfering RNAs targeting BAFF, APRIL, TACI, and BCMA inhibited HRS cell accumulation in vitro and might attenuate HL expansion in vivo.

DOI10.1182/blood-2006-04-015958
Alternate JournalBlood
PubMed ID16960154
PubMed Central IDPMC1785096
Grant ListR21 AI057130 / AI / NIAID NIH HHS / United States
R01 AI057530 / AI / NIAID NIH HHS / United States
R01 AI057653 / AI / NIAID NIH HHS / United States
AI057653 / AI / NIAID NIH HHS / United States
AI057530 / AI / NIAID NIH HHS / United States
R01 AI074378 / AI / NIAID NIH HHS / United States
Related Faculty: 
Amy Chadburn, M.D. Ethel Cesarman, M.D., Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700